Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success
The pharmaceutical industry is highly technical and incredibly competitive. That is on clear display right now in the…
3 Reasons Eli Lilly Remains a Buy
Eli Lilly (NYSE: LLY) became the first $1 trillion pharmaceutical company late last year, built on the strength…
US pharma giant Eli Lilly is very unhappy with Germany; CEO calls its planned healthcare reform: Terrible signal to …
US pharmaceutical giant Eli Lilly has announced that it is halving its massive €2.3 billion ($2.67 billion) investment…
Forget Zepbound: Eli Lilly’s Next Billion-Dollar Weight-Loss Drug May Be Even Better
Eli Lilly (NYSE: LLY) has been posting incredible sales and earnings growth in recent quarters, thanks in no…
Weight Loss Drugs Listed By Health Insurers Aren’t Necessarily Covered
Eli Lilly’s Foundayo weight loss oral pill competes against Novo Nordisk’s oral Wegovy. (Photo by: Michael Siluk/UCG/Universal Images…
An experimental GLP-1 pushes the limits of weight loss. There are risks.
Eli Lilly this month unveiled startling new data that showed an experimental weight-loss drug caused people with obesity…
From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Eli Lilly saw…
Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
By Bhanvi Satija and Chris Prentice LONDON/NEW YORK, May 21 (Reuters) – Lower prices for weight-loss pills from…
Could Eli Lilly’s Next Weight Loss Drug Waylay Wegovy — and Even Zap Zepbound?
After losing its market edge to Eli Lilly (NYSE: LLY) despite its first-mover advantage in weight-loss drugs, Novo…
Novo Nordisk’s high-dose Wegovy touts near 28% weight loss in early responders
Novo Nordisk has shared new data that suggests a higher dose version of its blockbuster weight loss drug,…
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients were…
Scoring 2 Million Prescriptions, Novo’s GLP-1 Pill Crushes Expectations
Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built…